Livzon Pharmaceutical Group Inc. (HKG: 1513)
Hong Kong
· Delayed Price · Currency is HKD
26.55
0.00 (0.00%)
Nov 21, 2024, 4:08 PM HKT
Livzon Pharmaceutical Group Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Jan '21 Jan 1, 2021 | Jan '20 Jan 1, 2020 | 2019 - 2015 |
Net Income | 2,025 | 1,954 | 1,909 | 1,776 | 1,715 | 1,303 | Upgrade
|
Depreciation & Amortization | 833.19 | 833.19 | 652.32 | 445.27 | 391.69 | 384.61 | Upgrade
|
Other Amortization | 54.71 | 54.71 | 33.31 | 26.07 | 31.7 | 30.88 | Upgrade
|
Loss (Gain) From Sale of Assets | 2.03 | 2.03 | 12.97 | -7.03 | 5.77 | -0.46 | Upgrade
|
Asset Writedown & Restructuring Costs | 0.57 | 0.57 | 0.16 | 6.15 | 72.28 | -0.99 | Upgrade
|
Loss (Gain) From Sale of Investments | -37.44 | -37.44 | 29.6 | -71.95 | -147.8 | 19.91 | Upgrade
|
Provision & Write-off of Bad Debts | 13.45 | 13.45 | 4.83 | 7.4 | 0.01 | 5.93 | Upgrade
|
Other Operating Activities | 373.59 | 349.26 | 204.44 | 341.21 | 467.33 | 205.91 | Upgrade
|
Change in Accounts Receivable | 466.29 | 466.29 | -660.45 | -664.68 | -491.93 | -81.1 | Upgrade
|
Change in Inventory | -334.42 | -334.42 | -498.57 | -232.01 | -400.35 | -108.34 | Upgrade
|
Change in Accounts Payable | -115.71 | -115.71 | 1,035 | 228.02 | 525.05 | 13.3 | Upgrade
|
Change in Other Net Operating Assets | 76.73 | 76.73 | 47.32 | 32.73 | 31.44 | 15.61 | Upgrade
|
Operating Cash Flow | 3,344 | 3,249 | 2,773 | 1,902 | 2,161 | 1,767 | Upgrade
|
Operating Cash Flow Growth | 6.61% | 17.18% | 45.75% | -11.96% | 22.27% | 39.41% | Upgrade
|
Capital Expenditures | -671.04 | -820.45 | -940.15 | -1,309 | -646.98 | -398 | Upgrade
|
Sale of Property, Plant & Equipment | 7.5 | 14.46 | 2.96 | 9.09 | 5.11 | 1.86 | Upgrade
|
Cash Acquisitions | - | -22.46 | - | - | - | - | Upgrade
|
Divestitures | - | - | - | 3.31 | 5.34 | - | Upgrade
|
Investment in Securities | -202.23 | -1.59 | -399.18 | -675.7 | 98.75 | 1.55 | Upgrade
|
Other Investing Activities | 84.01 | 121.67 | 106.5 | 95.5 | 69.93 | 78.56 | Upgrade
|
Investing Cash Flow | -781.77 | -708.37 | -1,230 | -1,877 | -467.84 | -316.02 | Upgrade
|
Long-Term Debt Issued | - | 3,658 | 3,714 | 2,800 | 2,384 | 1,509 | Upgrade
|
Total Debt Issued | 3,931 | 3,658 | 3,714 | 2,800 | 2,384 | 1,509 | Upgrade
|
Long-Term Debt Repaid | - | -3,149 | -2,827 | -2,055 | -1,830 | -1,650 | Upgrade
|
Net Debt Issued (Repaid) | 66.92 | 508.29 | 886.02 | 744.96 | 553.77 | -140.68 | Upgrade
|
Issuance of Common Stock | 161.75 | - | 42.25 | 202.56 | 352.26 | - | Upgrade
|
Repurchase of Common Stock | -346.15 | -346.15 | -56.04 | -238.18 | -250.06 | -0.03 | Upgrade
|
Common Dividends Paid | -1,370 | -1,590 | -1,591 | -1,257 | -1,100 | -868.46 | Upgrade
|
Other Financing Activities | -313.27 | -229.5 | -1.51 | -266.98 | -73.98 | -171.92 | Upgrade
|
Financing Cash Flow | -1,801 | -1,657 | -720.36 | -815.02 | -518.04 | -1,181 | Upgrade
|
Foreign Exchange Rate Adjustments | -34.34 | 20.04 | 124.89 | -37.15 | -77.01 | 20.42 | Upgrade
|
Net Cash Flow | 727.51 | 903.72 | 947.33 | -826.74 | 1,098 | 290.47 | Upgrade
|
Free Cash Flow | 2,673 | 2,428 | 1,833 | 593.23 | 1,514 | 1,369 | Upgrade
|
Free Cash Flow Growth | 9.89% | 32.52% | 208.91% | -60.81% | 10.56% | 72.62% | Upgrade
|
Free Cash Flow Margin | 22.55% | 19.54% | 14.51% | 4.92% | 14.39% | 14.59% | Upgrade
|
Free Cash Flow Per Share | 2.89 | 2.61 | 1.96 | 0.63 | 1.61 | 1.46 | Upgrade
|
Cash Income Tax Paid | 1,372 | 1,321 | 1,025 | 1,236 | 1,066 | 1,011 | Upgrade
|
Levered Free Cash Flow | 2,059 | 1,694 | 706.85 | -6.29 | 1,004 | 819.08 | Upgrade
|
Unlevered Free Cash Flow | 2,119 | 1,758 | 767.81 | 46.21 | 1,020 | 823.62 | Upgrade
|
Change in Net Working Capital | -355.18 | -412.66 | 232.66 | 347 | 56.43 | 69.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.